Clinical trial NCT02146937 (phase 2, status: withdrawn)
Conditions: detectable prostate nodules
ICD codes: A18.14, N41.2, N42.0, N42.83, C61, D29.1, N42.30
Drugs: bicalutamide plus finasteride- combination therapy
SMILES: [H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C
Reason stopped: 
    due to lack of accrual for this study. pi decided to close the study.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Willing and able to provide written informed consent.

          2. Age ≥ 18 years

          3. Eastern cooperative group (ECOG) performance status ≤2

          4. Documented histologically confirmed adenocarcinoma of the prostate (minimum 12 core
             prostate biopsy completed within 90 days of screening)

          5. Very low-risk prostate cancer as defined by:

               -  Gleason score ≤ 6

               -  PSA density ≤ 0.15 ng/mL/mL

               -  PSA < 10 ng/mL

               -  Clinical tumor stage T1 (cT1) (i.e., no palpable nodule by digital rectal exam)

               -  ≤2 prostate cores positive for prostatic adenocarcinoma

               -  ≤50% of any given core involved by prostatic adenocarcinoma

          6. Willing and qualified for active surveillance at Johns Hopkins

          7. Presence of at least one MRI significant visible prostate tumor (i.e., ≥5 mm in at
             least one dimension) that has been biopsy proven to be prostatic adenocarcinoma Note:
             MRI may occur pre- or post-prostate biopsy. If done post-biopsy, the MRI must not
             occur <8 weeks post-prostate biopsy.

          8. Serum testosterone ≥150 ng/dL

          9. Able to swallow the study drugs whole as a tablet

        Exclusion Criteria:

          1. Prior local therapy to treat prostate cancer (e.g., radical prostatectomy, radiation
             therapy, brachytherapy)

          2. Prior use of bicalutamide

          3. Prior use of finasteride within the past year

          4. Prior or ongoing systemic therapy for prostate cancer including, but not limited to:

               -  Hormonal therapy (e.g., leuprolide, goserelin, triptorelin)

               -  CYP-17 inhibitors (e.g., abiraterone, ketoconazole)

               -  Antiandrogens (e.g., bicalutamide, flutamide, nilutamide)

               -  Second generation antiandrogens (e.g., enzalutamide, ARN-509)

               -  Immunotherapy (e.g., sipuleucel-T, ipilimumab)

               -  Chemotherapy (e.g., docetaxel, cabazitaxel)

          5. Evidence of serious and/or unstable pre-existing medical, psychiatric or other
             condition (including laboratory abnormalities) that could interfere with patient
             safety or provision of informed consent to participate in this study.

          6. Any psychological, familial, sociological, or geographical condition that could
             potentially interfere with compliance with the study protocol and follow-up schedule.

          7. Abnormal bone marrow function [absolute neutrophil count (ANC)<1500/mm3, platelet
             count <100,000/mm3, hemoglobin <9 g/dL]

          8. Abnormal liver function (bilirubin, AST, ALT ≥ 3 x upper limit of normal)

          9. Abnormal kidney function (serum creatinine ≥ 2 x upper limit of normal)

         10. Abnormal cardiac function as manifested by NYHA (New York Heart Association) class III
             or IV heart failure or history of a prior myocardial infarction (MI) within the last
             five years prior to enrollment in the study.